June 2026: 

Loma Therapeutics Receives Second Innobooster

We are honored to have received a second Innobooster grant

The grant totals 5.000.000 DKK (~€670.000), which will advance the development of Loma’s novel HPV-targeted immunotherapy that holds the potential for effective treatment of HPV-positive cancers by elimination of the HPV infection. 

The support will be used for translational studies, profiling of immune responses, and advancement of the CMC developmental activities. 

We are very thankful for the support shown to us by the Innovation Fund Denmark.